QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

UBS analyst Marcus Cole maintains Amrize (NYSE:AMRZ) with a Neutral and raises the price target from $52 to $53.

Core News & Articles

Citigroup analyst Anthony Pettinari maintains Amrize (NYSE:AMRZ) with a Buy and raises the price target from $60 to $63.

Core News & Articles

Wells Fargo analyst Timna Tanners maintains Amrize (NYSE:AMRZ) with a Overweight and raises the price target from $57 to $58.

Core News & Articles

Amrize (NYSE:AMRZ) raises FY2025 sales outlook from $11.400 billion-$11.800 billion to $11.700 billion-$12.000 billion vs $11.7...

Core News & Articles

Amrize (NYSE:AMRZ) reported quarterly earnings of $0.98 per share which missed the analyst consensus estimate of $1.00 by 2 per...

Core News & Articles

UBS analyst Marcus Cole maintains Amrize (NYSE:AMRZ) with a Neutral and raises the price target from $49 to $52.

Core News & Articles

Wells Fargo analyst Timna Tanners initiates coverage on Amrize (NYSE:AMRZ) with a Overweight rating and announces Price Targ...

 darden-humana-and-rocket-lab-are-among-top-10-large-cap-losers-last-week-sep-15--sep-19-are-the-others-in-your-portfolio

Darden, Humana, Rocket Lab, and FactSet led last week's large-cap losers, with declines driven by weak earnings, guidance, ...

Core News & Articles

Oppenheimer analyst Bryan Blair initiates coverage on Amrize (NYSE:AMRZ) with a Outperform rating and announces Price Target...

Core News & Articles

JP Morgan analyst Adrian Huerta maintains Amrize (NYSE:AMRZ) with a Overweight and raises the price target from $52 to $60.

Core News & Articles

RBC Capital analyst Anthony Codling maintains Amrize (NYSE:AMRZ) with a Outperform and lowers the price target from $61 to $54.

Core News & Articles

Amrize, Meta and the University of Illinois partnership accelerates innovation and adoption of AI-optimized concrete mixesAdvan...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION